September 8, 2022

AstraZeneca Pharmaceuticals: The First and Only FDA-approved Agent for Reversal of FXa Inhibitor Activity in Patients with Life-threatening or Uncontrolled Bleeding

Saturday, October 1
2:30 p.m.– 3:15 p.m.
Location: Expert Theater 1


Dr. Gregory Fermann

Theater Information

This program will discuss the burden of life-threatening bleeds related to FXa inhibitors, and focus on the mechanism of action, efficacy, and safety of a reversal agent indicated for patients treated with anticoagulants who have life-threatening bleeding.

[ Feedback → ]